Efficacy of moxifloxacin, esomeprazole plus furazolidone triple therapy to eradicate Helicobacter pylori
- VernacularTitle:莫西沙星、埃索拉唑和呋喃唑酮三联根除幽门螺杆菌的疗效观察
- Author:
Bingsheng LI
;
Aihua GAN
;
Angao XU
;
Xinying WANG
;
Xiaohui ZHANG
;
Zhonggui YU
- Publication Type:Journal Article
- Keywords:
drug therapy;
Helicobacter pylori;
moxifloxacin;
furazolidone
- From:
Chinese Journal of Infection and Chemotherapy
2014;(4):273-275
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of 10-day moxifloxacin,esomeprazole plus furazolidone triple therapy as first-line treatment to eradicate Helicobacter pylori (Hp)in comparison with the 14-day quadruple therapy containing esomeprazole,amoxicillin, clarithromycin and colloidal bismuth pectin. Methods A total of 1 26 cases of endoscopically confirmed Hp-positive chronic active gastritis or peptic ulcer were randomly assigned to the treatment group to receive esomeprazole,moxifloxacin plus furazolidone triple therapy for 1 0 days;or to the control group to receive esomeprazole, amoxicillin,clarithromycin,and colloidal bismuth pectin quadruple therapy for 14 days.Clinical efficacy and safety were evaluated after 4-week treatment.Results At the end of treatment,the Hp eradication rate was 89.4%in the treatment group, and 88.3% in the control group(P>0.05).The incidence of adverse reactions in the treatment group (16.7%)was significantly lower than that in the control group (36.7%)(P<0.05).Conclusions The 10-day moxifloxacin,esomeprazole plus furazolidone triple therapy is effective and well-tolerated as first-line treatment to eradicate Hp with samilar efficacy and fewer adverse reactions compared to the 14-day bismuth-based quadruple therapy.
